MicroRNA expression in animal models of amyotrophic lateral sclerosis and potential therapeutic approaches

Bridget Martinez1,3, Philip V. Peplow3,*

Abstract

A review of recent animal models of amyotrophic lateral sclerosis showed a large number of miRNAs had altered levels of expression in the brain and spinal cord, motor neurons of spinal cord and brainstem, and hypoglossal, facial, and red motor nuclei and were mostly upregulated. Among the miRNAs found to be upregulated in two of the studies were miR-21, miR-155, miR-125b, miR-146a, miR-124, miR-9, and miR-19b, while those downregulated in two of the studies included miR-146a, miR-29, miR-9, and miR-125b. A change of direction in miRNA expression occurred in some tissues when compared (e.g., miR-29b-3p in cerebellum and spinal cord of wobbler mice at 40 days), or at different disease stages (e.g., miR-200a in spinal cord of SOD1(G93A) mice at 95 days vs. 108 and 112 days). In the animal models, suppression of miR-129-5p resulted in increased lifespan, improved muscle strength, reduced neuromuscular junction degeneration, and tended to improve motor neuron survival in the SOD1(G93A) mouse model. Suppression of miR-155 was also associated with increased lifespan, while lowering of miR-29a tended to improve lifespan in males and increase muscle strength in SOD1(G93A) mice. Overexpression of members of miR-17–92 cluster improved motor neuron survival in SOD1(G93A) animals. Treatment with an artificial miRNA designed to target hSOD1 increased lifespan and improved muscle strength in SOD1(G93A) mice. Further studies with animal models of amyotrophic lateral sclerosis are warranted to validate these findings and identify specific miRNAs whose suppression or directed against hSOD1 results in increased lifespan, improved muscle strength, reduced neuromuscular junction degeneration, and improved motor neuron survival in SOD1(G93A) animals.

Key Words: amyotrophic lateral sclerosis; animal model; brain; brainstem; microRNA; motor neuron degeneration; spinal cord; therapeutic approaches

Introduction

The most common motor neuron (MN) disease in adults is amyotrophic lateral sclerosis (ALS) (Shaw and Eggett, 2000), with a worldwide annual incidence rate of approximately 2–3 cases per 100,000 people (Kiernan et al., 2011; Al-Chalabi et al., 2016). Irreversible and progressive degeneration of MNs in the motor cortex, brainstem and spinal cord characterize the clinical phenotype (Bucchia et al., 2015). Aggregations of misfolded proteins, disorders of axonal transport, mitochondrial dysfunction, excitotoxicity, neuroinflammation, and altered RNA processing are pathological characteristics of ALS (Brown and Al-Chalabi, 2017).

In most spinal-onset ALS patients, the MN subtype innervating distal limbs is the first to degenerate with patients initially experiencing muscle weakness or atrophy in the arms or legs (Kanning et al., 2010; Swinnen and Robberecht, 2014). Subsequently additional MN subtypes are affected and usually within 3–5 years after diagnosis patients experience complete paralysis and die from respiratory failure. Currently no effective treatments are available for ALS; thus, highlighting the need to further identify mechanisms that can serve as therapeutic targets. Riluzole is a previously approved drug for ALS and has a small beneficial effect on bulbar and limb function, improving patient survival by about two months (Miller et al., 2012). A new drug Edaravone approved by the US Food and Drug Administration showed efficacy in a small subset of individuals with ALS who met well-defined criteria. However, there was no indication that it might be effective in a wider population of ALS patients who do not meet the criteria (Abe et al., 2017).

Most ALS patients are classified as sporadic and only 5–10% of cases have a familial history (Renton et al., 2014; Chia et al., 2018). Mutations in or deletion of the Cu/Zn superoxide dismutase 1 (SOD1) gene are the most studied genetic causes of ALS (Rosen et al., 1993). Other genes associated with ALS include TARDBP, encoding transactive response DNA-binding protein 43 (TDP-43), fused in sarcoma (FUS), and C9orf72 (Kabashi et al., 2008; Sreedharan et al., 2009; Yokoseki et al., 2008; Kwiatkowski et al., 2009; Vance et al., 2009; DeJesus-Hernandez et al., 2011). While 40% of familial ALS (fALS) patients carry a mutation in the C9orf72 gene (Majounie et al., 2012), the large number and variety of identified SOD1 mutations found in 20% of fALS cases have made this an extensively used experimental model (Renton et al., 2011, 2014).

Many of the identified ALS-associated genes encode for RNA-binding proteins such as TDP-43, FUS, and heterogeneous nuclear ribonucleoprotein A1 (Buratti et al., 2010; Kawahara...
and Mieda-Sato, 2012; Morlando et al., 2012). Moreover, many of these fALS-associated genes are involved in microRNA (miRNA) biogenesis (Guil and Caceres, 2007; Goodall et al., 2013; Gascon and Gao, 2014). MiRNA expression has been examined in MN diseases (Vance et al., 2009; Haramati et al., 2010; Butovsky et al., 2015; Emde et al., 2015; Parisi et al., 2016). An overall decrease of mature miRNAs and altered miRNA processing were found in postmortem spinal cord samples of ALS patients (Figueroa-Romero et al., 2016). Altered expression of specific miRNAs was observed in the cerebrospinal fluid (CSF), serum and leukocytes of ALS patients (De Felice et al., 2014; Freischmidt et al., 2015; Takahashi et al., 2015; Benigni et al., 2016; Tasca et al., 2016). While an altered miRNA expression in ALS patients and mouse models has been reported (Yee and Goncalves Ido, 2014; Eitan and Hornstein, 2016), the roles and sets of miRNAs involved in ALS are not fully known. Onset of MN loss in a fALS-SOD1(G93A) mouse model was shown to be accelerated by loss of the muscle-specific miRNA, miR-206 (Williams et al., 2009), but whether MN-specific miRNAs could serve as potential therapeutic targets is unclear. A large number of miRNAs have been shown to be dysregulated in various ALS tissues (Russell et al., 2013; Paez-Colasante et al., 2015; Figueroa-Romero et al., 2016) with an overall downregulation of miRNAs in MNs of ALS patients (Emde et al., 2015). MiRNAs have been found either upregulated or downregulated in ALS spinal cord, muscle tissue, and peripheral blood mononuclear cells (Yee and Goncalves Ido, 2014). Alterations in neuronal fate of cultured ependymal stem/progenitor cells isolated from the spinal cord of ALS mice were significantly associated with the expression of neuronal (miR-9, miR-124a) and cell cycle-related (miR-19a, miR-19b) miRNAs, and became more pronounced as the disease progressed (Marcuzzo et al., 2014). However, it is unclear to what extent these dysregulated miRNAs influence the disease onset, progression, and severity. Impaired RNA processing and stability may contribute to the development of ALS (Droppelmann et al., 2014). The aim of this review was to provide an analysis of recent literature on the expression levels and possible roles of miRNAs in ALS animal models and their potential for guiding therapeutic design.

Animal Models of Amyotrophic Lateral Sclerosis

Mouse and other animal models are necessary for studying ALS, which is a collection of diseases that involve different systems, including the immune system. Specific disease courses occur in different animal models, which is also likely in ALS patients. Thus, it is important to use different models to study ALS pathogenic mechanisms more completely. Two main types of animal models have been developed, toxin-induced models and genetic models.

Toxin-induced models

β-Sitosterol-β-D-glucoside treatment in mice

 Dietary treatment of β-sitosterol-β-D-glucoside (BSSG), a common plant sterol present in high amounts in cycad flour, has been used to develop a mouse model of sporadic ALS (sALS). Progressive motor neuron degeneration occurred in mice fed the flour made from raw washed cycad seeds or the synthesized form of BSSG, and intensified after BSSG exposure was discontinued. The model mimicked many features of human ALS disease with loss of motor neurons, reduced neuromuscular junction (NMJ) integrity, astrocytosis, evidence of microgliosis, and neuronal cell death in pathologically relevant CNS regions (Wilson et al., 2002; Tabata et al., 2008). BSSG treatment in rats results in animals showing cognitive deficits marked by progressive degeneration in the substantia nigra pars compacta, and more closely resembles a parkinsonian phenotype (Van Kampen et al., 2015).

Genetic models

The wobbler mouse model

The wobbler mouse was the first proposed mouse model of ALS (Duchen and Strich, 1968) and it arose by spontaneous mutation in a C57BL/Fa mouse strain (Falconer, 1956). A single leucine to glutamine base pair exchange in the last exon of the vacuolar-vascular protein sorting factor 54 gene was identified (Schmitt-John et al., 2005). Wobbler mice exhibit an ALS-like phenotype with muscle atrophy, unsteady gait, decreased body weight, and tremor. A major advantage of wobbler mice is they show nearly all clinical hallmarks of human ALS patients (Duchen and Strich, 1968; Bruijn et al., 2001). The only symptom lacking in the wobbler mice is frontotemporal dementia, which appears in ~10% of human ALS cases, and cannot be evaluated in the mouse model (Achi and Rudnicki, 2012). Pathologies in common with human ALS include axonal transport impairment, ubiquitin-positive protein aggregation, upper and lower MNs degeneration, and enlarged endosomes vacuolization (Duchen and Strich, 1968; Mitsuomto et al., 1990; Ferriauolo et al., 2001; Dennis and Citron, 2009; Palmisano et al., 2011; Moser et al., 2013). In the first three postnatal weeks (from 0 to 20 days), no clinical abnormalities are seen in homozygous wobbler mice and no differences are observed between wobbler mice and wild type (WT) littermates (Ott et al., 2015). Following the preclinical stage (20 days of age), the first symptoms start to appear such as head tremor, unsteady gait or muscle weakness of the front limbs (Duchen and Strich, 1968; Boillée et al., 2003). At 40 days of age, the clinical phenotype is fully developed in homozygous wobbler mice (Saberi et al., 2016).

SOD1 animal models

Mice and rats with mutations in the SOD1 gene develop MN degeneration and muscle atrophy (Gurney, 1994). Although the exact pathological role of SOD1 in ALS is unclear, a series of transgenic mice carrying ALS SOD1 mutants has been established. NMJ dysfunction within limb muscles, with limb movement impairment, is seen very early as the first sign of disease onset in these mice (Pun et al., 2006). Subsequently, NMJs degenerate in the diaphragm (Rocha et al., 2013).

The SOD1(G93A) transgenic mouse model overexpresses the G93A mutated human SOD1 gene, and exhibits symptoms and neuropathological features similar to those of human ALS patients (Gurney, 1997). Skeletal muscle atrophy occurs in SOD1(G93A) mice at a very early stage in the absence of motor symptoms or neurodegenerative changes in brainstem MNs (Marcuzzo et al., 2011). A rapid degeneration of MNs leading to paralysis and death within the first 5 months of age occurs in this model (Nardo et al., 2016). Upper MN deficits are absent in this model.

While the SOD1(G93A) mouse model has been the most used and studied animal model of ALS, other SOD1 mouse models have been developed with mutations outside G93A (e.g., G37R, G85R, G86R) (Philips and Rothstein, 2015). These models develop adult-onset progressive MN disease, with varying degree of age of onset and disease progression rates. In SOD1(G93A) mice, disease onset usually occurs at 3 months of age and survival is to 4–5 months of age. By contrast, in SOD1(G37R) mice, disease onset usually occurs at 3.5–6 months of age and survival is to 7 months of age. For SOD1(G85R) mice, disease onset is at 8 months of age and survival is to 8.5 months of age.

FUS mouse models

Several FUS mouse models have been generated by insertion of human wild type FUS or knockout of FUS. Transgenic mice overexpressing wild type human FUS exhibited an early onset tremor followed by progressive hind limb paralysis and death by 12 weeks in homozygous animals. There was loss of large MNs from the spinal cord accompanied by denervation and...
Review

muscle atrophy. Surviving MNs in the spinal cord had greatly increased cytoplasmic expression of FUS, with FUS-positive and ubiquitin-negative inclusions associated with astroglial and microglial reactivity. Cytoplasmic FUS inclusions occurred in the brain of transgenic mice without apparent neuronal loss and little astroglial and microglial activation. Hemizygous FUS overexpressing mice did not show any evidence of a motor phenotype or pathology (Mitchell et al., 2013).

**FVB-C9orf72 BAC mouse model**
A hexanucleotide repeat expansion in chromosome 9 open reading frame 72 was identified as a gene mutation associated with fALS and with those affected carrying between 23 and 5000 repeat sequences (Al-Chalabi and Hardiman, 2013; Haeusler et al., 2014). While many different rodent models of C9orf72 have been developed, the FVB-C9orf72 BAC transgenic mouse model harboring a large repeat expansion (C9-500) was reported by Liu et al. (2016) to develop many features similar to ALS including paralysis, MN loss, impaired NMJ integrity, RNA foci formation, dipeptide repeat protein aggregation, TDP-43 cytoplasmic aggregation, and decreased lifespan. However, a recent study of C9orf72 BAC C9-500 mice of up to 1 year revealed no reproducible abnormalities in motor function, neuronal loss, or survival (Mordes et al., 2020), and these findings were consistent with the first investigations of C9orf72 BAC transgenic mouse models which were unable to detect motor deficits or decreased survival (O’Rourke et al., 2015; Peters et al., 2015). Possible explanations for the differences in findings include the housing environment may contribute to phenotypic manifestations in C9-500 animals or could be due to differences in genetic background on which the model was created. Furthermore, the study by Liu et al. (2016) employed relatively small numbers of C9-500 mice and controls, together with the relatively high frequency at which FVB/N-related phenotypes occur, raises the possibility that misassignment of effect to the C9-500 transgene may have occurred (Mordes et al., 2020). C9-BACexp mice containing the full human C9orf72 gene with disease-associated expansion (~100–1000 repeats) exhibited pathological features observed in C9orf72 transgenic expansion patients including widespread RNA foci and repeat-associated non-ATG translated dipeptides (O’Rourke et al., 2015).

**TDP-43-Q331K mouse model**
Approximately 20 different mouse models of TDP-43 have been developed (Lutz, 2018). The TDP-43-Q331K mouse model is based on mild overexpression of human mutant TDP-43 (Arnold et al., 2013), with the degenerative phenotype not caused by human wild type TDP-43. The TDP-43-Q331K model shows many ALS-like features such as progressive motor dysfunction, muscle atrophy, decreased NMJ integrity, and MN degeneration at 10 months of age. The motor phenotype only involves lower MNs, the progressive degeneration stops at 20 months, and the ALS-like outcomes do not cause death. In addition, no TDP-43 cytosolic aggregation or nuclear export occurs in this model (Arnold et al., 2013; Philips and Rothstein, 2015; Lutz, 2018). Ubiquitinated TDP-43 cytoplasmic inclusions have been observed in other mutant TDP-43 mouse models (Xu et al., 2010; Stribel et al., 2014).

**MicroRNAs in Animal Models of Amyotrophic Lateral Sclerosis**
We performed a PubMed search of articles published from January 2012 to August 2020 to examine microRNAs with altered expression in brain, spinal cord, and motor neurons in animal models of amyotrophic lateral sclerosis. The study by Liu et al. (2016) employed relatively small numbers of C9-500 mice or could be due to differences in genetic background on which the model was created. Furthermore, the study by Liu et al. (2016) employed relatively small numbers of C9-500 mice and controls, together with the relatively high frequency at which FVB/N-related phenotypes occur, raises the possibility that misassignment of effect to the C9-500 transgene may have occurred (Mordes et al., 2020). C9-BACexp mice containing the full human C9orf72 gene with disease-associated expansion (~100–1000 repeats) exhibited pathological features observed in C9orf72 transgenic expansion patients including widespread RNA foci and repeat-associated non-ATG translated dipeptides (O’Rourke et al., 2015).

**MiRNAs in spinal cord of SOD1(G93A) mice**
Loffreda et al. (2020) found using RT-qPCR that the expression of miR-129-5p and miR-200c was increased at the early symptomatic stage (15 weeks of age) and that of miR-206 was increased at the pre-onset (10 weeks), early symptomatic (15 weeks), and end stage (22 weeks) of the disease in the lumbar spinal cord of SOD1(G93A) female mice. The numbers of ChAT-containing MNs in SOD1(G93A) lumbar spinal cords were shown by Tung et al. (2019) to be relatively unaffected before 80 days of age and slightly decreased at 100 days of age. At 80 days of age, a significant downregulation of miR-17 expression in SOD1(G93A) MNs was found by RT-qPCR. At 100 days of age, the expression of ChAT was unchanged between the microdissected Ctrl and SOD1(G93A) MNs, but several members of the miR-17–92 cluster (miR-17, miR-18a, miR-20a) had significantly decreased expression in SOD1(G93A) MNs. Together with the downregulation of miR-17–92 cluster, an associated increase was observed in the expression of its targets PTEN, Nedd4-2, and Ndfip1 in SOD1(G93A) MNs at 100 days of age.

Using in situ hybridization (ISH), Zhou et al. (2018) detected several gliosis-related miRNAs including miR-146a, miR-219, miR-21, and miR-124 in the spinal cord and brainstem of SOD1(G93A) mice. MiR-146a was significantly decreased but miR-129 was significantly increased at the three stages of disease (95, 108, and 122 days of age) in the ventral horn of the spinal cord and the hypoglossal, facial, and red motor nuclei of SOD1(G93A) mice compared with WT mice. MiR-21 was upregulated in the spinal cord but decreased in the red motor nuclei and facial and hypoglossal nerve nuclei at 95, 108, and 122 days of age in SOD1(G93A) mice compared with WT mice. The expression of several apoptosis-related miRNAs including miR-181a, miR-22, miR-26b and miR-34a in the spinal cord and brainstem of ALS transgenic mice was measured. There was an increased expression of miR-181a, whereas miR-22, miR-26b, and miR-34a had decreased expression at the three different stages of disease in the spinal cord and hypoglossal, facial, and red nuclei of SOD1(G93A) mice compared with WT mice. The expression of miR-
200a and miR-320 in the spinal cord and brainstem of ALS transgenic mice was also altered. MiR-200a was increased at 95 days but decreased at 108 and 122 days in the spinal cord and hypoglossal, facial and red nuclei of SOD1(G93A) mice compared with WT mice. MiR-320 was decreased at the three stages of disease in the spinal cord and hypoglossal, facial and red nuclei of SOD1(G93A) mice. The expression of mir-124 was increased at 95 days but decreased at 108 and 122 days in the spinal cord and hypoglossal, facial, and red nuclei of SOD1(G93A) mice compared to WT mice. The expression of selected miRNAs in the coccus motor nerve nucleus was unchanged in SOD1(G93A) mice compared with WT mice. MiR-124-positive cells were found mainly in the ventral horn of the spinal cord and hypoglossal, facial, and red nuclei of SOD1(G93A) mice. The expression of mir-124 was increased at 95 days but decreased at 108 and 122 days in the spinal cord and hypoglossal, facial, and red nuclei of SOD1(G93A) mice compared to WT mice. The expression of selected miRNAs in the spinal cord was confirmed by qRT-PCR. MiR-219, mir-21 and mir-181a were increased at 95, 108, and 122 days of age in SOD1(G93A) mice compared with WT mice, while mir-146a, miR-22, miR-26b, miR-34a, and MiR-320 were decreased at these three different stages of disease. In addition, levels of mir-200a and mir-124 were increased, while those of mir-200a and mir-124 were decreased, in SOD1(G93A) mice at 95 days of age.

Higher levels of hSOD1 expression were observed in SOD1(G93A) male mice at both symptomatic (4–6 weeks of age) and symptomatic phase (12–14 weeks) of the disease than in WT animals by Cunha et al. (2016). The number of MNs was only decreased in SOD1(G93A) mice at the symptomatic stage. Pyknotic basophilic necrotic/apoptotic MNs were shown by H&E staining at the symptomatic stage of SOD1(G93A) mice, together with an increased number of glial cells. In the presymptomatic stage, an increased expression of mir-155 was observed by RT-PCR, together with a decreased expression of its direct target, the suppressor of cytokine signaling 1 (SOCS1) (Pathak et al., 2015). The existence of a neuroinflammatory status after disease onset was indicated by the sustained increase of mir-155, as well as decreased expression of anti-inflammatory associated marker SOCS1, together with Arg1 subexpression. Decreased GFAP expression indicated an astrocyte abnormality (Diaz-Amarilla et al., 2011). Various proinflammatory miRNAs such as miR-155, miR-21, miR-146a, miR-125b, and miR-124 have been associated with different phenotypes and functions of microglia in ALS (Brites and Vaz, 2014). Among them, only miR-155 was significantly upregulated in the spinal cord of asymptomatic SOD1(G93A) mice. This indicated that miR-155 upregulation occurred earlier, before disease onset, and in the absence of other common proinflammatory miRNAs. In the symptomatic stage, there was evidence of an increased inflammatory status in the spinal cord of SOD1(G93A) mice as shown by upregulated inflammatory signaling pathways involving NF-kB and its active phosphorylated form pNF-kB, increased Nlrp3, IL-1beta, Tnfa expression, as well as elevated HMGB1 cellular content. Increased expression of mir-155 was observed, but at this stage together with mir-125b, miR-146a, miR-21, and miR-124 significantly increased expression. Mir-155 and miR-125b are associated with proinflammatory responses and NF-kB activation (Ponomarev et al., 2013; Volonte et al., 2015; Cunha et al., 2016). MiR-146a and miR-21, also produced after NF-kB activation, act as feedback negative regulators to restrain microglia activation (Saba et al., 2012; Ponomarev et al., 2013). MiR-124 also influences microglia to adopt either a surveilling state or an anti-inflammatory phenotype (Ponomarev et al., 2011, 2013).

Hoye et al. (2017) found that six miRNAs were increased in either spinal cord or brainstem MNs compared with all other neurons in SOD1(G93A) mice. Using individual RT-qPCR assays at a higher power (n = 6), mir-218-5p, miR-218-2-3p, miR-138, miR-133a, miR-1193 had increased expression. MiR-218-5p and its lesser abundant 3p strand had the greatest increase in adult MNs compared with all other spinal cord neurons. The increase of miR-218 in adult mouse spinal cord MNs was confirmed by ISH. MiR-218 was detected principally in the ChAT+ MNs in the anterior horns of the spinal cord but not in other cell types. RT-qPCR was performed on SOD1(G93A) spinal cord collected at 56, 84, 105, 126, and 147 days of age, as well as end stage (indicated by an animal’s inability to right itself within 30 seconds). In the SOD1(G93A) mouse model, disease onset typically occurs at ~130 days of age as marked by time to peak weight. The Mn-enriched miRNAs miR-218 and miR-138 had a significant temporal depletion in SOD1(G93A) mouse spinal cords beginning as early as 126 days of age, and was maximized in the end stage. Pan-neuronal enriched miRNAs miR-382 and miR-672 were decreased but not significantly depleted in ALS mouse model spinal cord, even at end stage. In ALS model rats, disease onset similarly occurred between 120 and 140 days of age, and as in ALS mice, Mn-enriched miRNAs were more significantly depleted than pan-neuronal miRNAs in SOD1(G93A) rat spinal cords. In whole SOD1(G93A) mouse spinal cord tissue, miR-218 was not significantly depleted until 126 days of age. MiR-218 levels were not significantly changed in the surviving MNs from the presymptomatic (70 days) to symptomatic (140 days) time points in ALS mice. By miR-218 ISH using spinal cord tissue from 140 days of age SOD1(G93A) and littermate control mice, the miR-218 fluorescence signals were also not significantly different, but the numbers of ChAT+ MNs per unit area were significantly altered, confirming that ChAT+ MNs were lost in ALS mouse spinal cords.

Parisi et al. (2016) observed by RT-PCR that the expression of miR-125b, similar to that of NADPH oxidase 2 (NOX2) mRNA, was significantly increased in lumbar spinal cord of SOD1(G93A) mice at end stage (~23 weeks of age) compared to non-transgenic mice, whereas the level of A20 protein was significantly decreased as indicated by Western blotting analysis. The enzyme A20 has anti-inflammatory functions and is a feedback-loop suppressor of NF-kB signaling to stop the inflammatory response of several stimuli such as TNF-α and LPS (Boone et al., 2004; Turer et al., 2008; Coornaert et al., 2009).

Using RT-PCR, Marcuzzo et al. (2015) showed at 18 weeks the expression levels of miR-9 and miR-124a, but not miR-134, were significantly decreased, whereas miR-19a and miR-19b expression levels were significantly increased, in SOD1(G93A) whole spinal cord compared to WT-SOD1 spinal cord. Expression of miR-125b and miR-219 tended to be increased (although not statistically significant) in cervical, thoracic and lumbar spinal cord of SOD1(G93A) mice compared to control mice.

Dobrowolny et al. (2015) examined the expression of miRNAs in the lumbar spinal cord of Myosin Light Chain (MLC)/SOD1(G93A) mice overexpressing mutant SOD1 gene under the control of MLC muscle specific promoter, 4 months of age, and FVB (Friend leukemia virus B) (control strain), 4 months of age. By RT-PCR, the expression of miR-133a, miR-133b, miR-9, miR-29, miR-330, and miR-1 was significantly decreased in the spinal cord of MLC/SOD1(G93A) mice compared to WT mice. Also, by RT-PCR for mRNA expression of genes involved in the myelination process, Pmp22, Prx, Mpz, Egr2 were significantly increased in the spinal cord of MLC/SOD1(G93A) mice, while Opalin was significantly decreased, compared to WT mice, consistent with these factors being targets of specific miRNAs that control denervation and reinnervation processes.

Using RT-qPCR, Nolan et al. (2014) found miR-29a to be increased in lumbar spinal cord from SOD1(G93A) mice at presymptomatic (70 days of age) and symptomatic (90 days of age) phase compared to SOD1 WT mice. The RT-qPCR analysis was validated by ISH using miR-29a-specific digoxigenin-labeled hybridization probes. MiR-29a was shown
to be expressed in the gray matter of the lumbar spinal cord. Expression of miR-29a was present in SOD1(G93A) mice at 70 days of age, with very weak miR-29a staining in sections from WT mice. Overlap in miR-29a expression and the position of Nissl-stained MNs on consecutive sections suggested that miR-29a was expressed in MNs, among other cell types.

Zhou et al. (2013) found by RT-qPCR that miR-9 levels in the spinal cord of SOD1(G93A) mice were significantly higher than those in WT mice at early (95 days of age), middle (108 days) and late (122 days) stages of the disease. ISH indicated that miR-9 was localized in the cytoplasm of the positive cells. The miR-9-positive cells were mainly detected in the gray matter of the ventral horn and the dorsal horn of the spinal cord of SOD1(G93A) and WT mice at the different time points, with the majority being located in the gray matter of the ventral horn, the site of neurodegeneration. The number of miR-9-positive cells was significantly increased at 95, 108, and 122 days of age in the SOD1(G93A) mice compared to WT mice. MiR-9 is involved in the proliferation and differentiation of neural stem cells (NSCs).

By microarray analysis, Koval et al. (2013) showed that 12 miRNAs were significantly increased in the spinal cord of SOD1(G93A) mice at end stage, including miR-155.

**MiRNAs in cortical tissue of SOD1(G93A) mice**

A significantly decreased expression of both NeuN and ChAT proteins was reported by Gomes et al. (2019) in cortical tissue from SOD1(G93A) mice at symptomatic stage, 12–14 weeks of age, but not at presymptomatic stage, 4–6 weeks, indicating a pronounced loss of neurons, mainly of MNs (~40%). A significantly decreased expression of the presynaptic SYP and postsynaptic PSD-95 proteins occurred at symptomatic stage. As miR-124 was shown to regulate synaptic structure and function (Hou et al., 2015) and miR-125b to be involved with neurite outgrowth (Le et al., 2009), their expression was measured in cortical tissue by RT-PCR. The expression of miR-124 was not altered, but that of miR-125b was significantly decreased at symptomatic stage. MiRNAs have been shown to play a critical role in neuroinflammation and differentially expressed in ALS (Volonte et al., 2015). Expression of both miR-21 and miR-146a in the cortical tissue of SOD1(G93A) mice was significantly decreased at symptomatic stage. MiR-146a expression was also significantly decreased at presymptomatic stage, highlighting miR-146a as an early biomarker of the disease. Expression of miR-155 was significantly decreased at symptomatic stage compared to presymptomatic stage, indicating a decrease in miR-155 expression with disease progression in the cerebral cortex.

**MiRNAs in whole brain, brain regions of SOD1(G93A) mice**

Using RT-PCR, Marcuzzo et al. (2015) showed that the expression levels of miR-9, miR-124a, and miR-19b did not differ significantly between whole brains of SOD1(G93A) mice at 8 weeks of age (presymptomatic), B6.SJL and WT-SOD1 mice, while that of miR-19a was significantly downregulated in ALS brain. However, at 18 weeks (late stage disease), expression levels of miR-9, miR-124a, miR-19a and miR-19b were significantly higher in SOD1(G93A) brains than control brains. In addition, miR-9 was significantly upregulated in SOD1(G93A) brain compared to 8 weeks, while miR-19a was significantly downregulated in SOD1(G93A) brain compared to 8 weeks. MiRNA expression was examined in specific brain regions of 18-week-old ALS mice concerned with neurogenesis (SVZ and hippocampus) and those affected by ALS (primary motor cortex and brainstem MN). MiR-124a expression was significantly higher in SVZ, hippocampus, primary motor cortex, and brainstem MN of ALS than WT-SOD1 mice. MiR-9 expression was significantly lower in SVZ and hippocampus, and significantly higher in primary motor cortex and brainstem MN in ALS compared to WT-SOD1 mice. MiR-19a expression was significantly decreased in hippocampus and brainstem MN and significantly increased in primary motor cortex of SOD1(G93A) mice compared to control. MiR-19b expression was significantly increased in hippocampus and significantly decreased in primary motor cortex and brainstem MN of SOD1(G93A) mice compared to control. MiR-125b expression was significantly decreased in SVZ and hippocampus and significantly increased in primary motor cortex of SOD1(G93A) mice compared to control.

**MiRNA biogenesis pathway in the brain and spinal cord of SOD1(G93A) mice**

Russell et al. (2018) found no differences in the mRNA levels of Drosha and Xpo5 in brain tissue or cervical, thoracic, and lumbar regions of the spinal cord in SOD1(G93A) mice at 99–137 days of age compared to the same tissue in WT mice. The mRNA levels of ALS-related genes that regulate the miRNA biogenesis pathway were measured. Except for an increase in mRNA level of Fus in the lumbar region of the spinal cord in SOD1(G93A) mice at 99–137 days, there were no differences in the brain tissue or in the cervical, thoracic, and lumbar regions of the spinal cord of SOD1(G93A) mice compared to the same tissue in WT mice.

**MiRNAs in the spinal cord of wobbler mice**

In a study by Klatt et al. (2019), cervical spinal cord was collected from WT and wobbler mice at presymptomatic (0 days of age, i.e., at birth) and stable symptomatic phase (40 days of age). By qRT-PCR, a highly significant upregulation of miR-29b-3p was found in the spinal cord of wobbler mice at 0 days of age, and a highly significant downregulation at 40 days of age. By ISH, miR-29b-3p staining was mainly within the gray matter of the spinal cord of WT mice. By qPCR, no alteration in mRNA levels of BCL-2-modifying factor (BMF) in the spinal cord of wobbler mice occurred at 0 and 40 days of age. There was a significant decrease of BMF protein expression in the spinal cord of wobbler mice at 0 days of age followed by a nonsignificant decreased protein expression at 40 days of age.

**MiRNAs in the cerebellum of wobbler mice**

Klatt et al. (2019) collected cerebellar tissue from WT and wobbler mice at presymptomatic (0 days of age, i.e., at birth) and stable symptomatic phase (40 days of age). Using qRT-PCR analysis, a highly significant decrease of miR-29b-3p expression occurred in the cerebellum of wobbler mice at 0 days of age, together with a highly significant increase of miR-29b-3p expression at 40 days of age. In a study by Klatt et al. (2019), cervical spinal cord was collected from WT and wobbler mice at presymptomatic (0 days of age) and stable symptomatic phase (40 days of age). Using qRT-PCR analysis, a highly significant decrease of miR-29b-3p expression occurred in the cerebellum of wobbler mice at 0 days of age, together with a highly significant increase of miR-29b-3p expression at 40 days of age. In a study by Klatt et al. (2019), cervical spinal cord was collected from WT and wobbler mice at presymptomatic (0 days of age) and stable symptomatic phase (40 days of age). Using qRT-PCR analysis, a highly significant decrease of miR-29b-3p expression occurred in the cerebellum of wobbler mice at 0 days of age, together with a highly significant increase of miR-29b-3p expression at 40 days of age.

**MiRNAs as potential therapeutic targets in SOD1(G93A) mice**

Loffreda et al. (2020) treated adult SOD1 mice (with a nearly equal number of males and females) with an intracerebroventricular (i.c.v.) injection of a morpholino (MO)
sequence targeting the miR-129-5p precursor, miR-129-1 (40 nmoles, n = 14) or ctr-MO (n = 12) at the early symptomatic phase (80 days of age). The ability of MO in decreasing miR-129 expression was shown by treating WT pups i.c.v. with 24 nmoles MO and harvesting spinal cords after 1 week when RT-qPCR analysis showed a significant decrease of miR-129-5p expression levels after treatment. ELAVL4/HuD mRNA is a target of miR-129-5p, and there was a significant increase in the level of the RNA-binding protein ELAVL4/HuD in the same mice. The lifespan of MO-treated SOD1 mice was significantly increased and muscle strength was also increased. At 120 days of age there was a trend toward reduced MN loss in the lumbar spinal cord of MO-treated SOD1 mice and a significant increase in the number of fully innervated NMs compared to ctr-SOD1 mice.

MiR-17–92 was overexpressed in the whole spinal cord of SOD1(G93A) mice by intrathecal injection of a self-complementary adeno-associated vector serotype 9 (scAAV9) at 60 days of age by Tung et al. (2019). The efficiency of virus injection was tested by injecting scAAV9-GFP to Ctrl mice, and sustained GFP expression was observed in spinal MNs and also in some dorsal cells at 40 days post-injection. Pronounced induction of exogenous miR-17–92 in the spinal cord of Ctrl and SOD1(G93A) mice injected with scAAV9-GFP was verified by ISH of miR-17 as well as RT-qPCR quantification of miR-17–92 members in the lumbar spinal cord. Measurement of evoked compound muscle action potential (CMAP) in gastrocnemius muscle was performed. At 60 days of age, SOD1(G93A) mice had just started to show MN denervation and exhibited a slightly compromised CMAP amplitude. AAV9-miR-17–92 treatment significantly increased the CMAP response at 120 and 140 days of age but had not yet improved to the level of Ctrl mice. The data suggested that miR-17–92 overexpression enhanced MN survival significantly rather than promoted MN reinnervation, and also increased survival of the mice.

Butovsky et al. (2015) produced F2-SOD1(G93A)/miR-155+/− and SOD1(G93A)/miR-155−/− mice which had a deletion of one or two miR-155 alleles. Genetic deletion of miR-155 increased lifespan by 51 days in females (n = 9–10/group) and by 27 days in males (n = 9–10/group), extended the time to reach a neuromuscular score of 1 by 62 days in females and 58 days in males, improved rotarod performance, decreased body weight loss, and delayed early and late disease onset in females. Early phase onset was delayed in males, but late phase was not significantly affected by genetic deletion of miR-155. SOD1 mice were treated with anti-miR-155 given both peripherally and intrathecally to assess whether treatment affected miR-155 targeted genes and increased lifespan. LNA-anti-miR-155 and scrambled LNA-anti-miR-155 were used. 2 mg/kg of anti-miR-155 was administered intraperitoneally beginning at disease onset as defined by body weight loss of 5% of mouse maximal weight (82 days of age) twice weekly (82, 85, 92, 95, 103 days of age) for a total of 5 injections (ending on day 103). Increased rotarod performance, delayed time to reach a neuroscore of 1 (6.5 days), and increased survival (11 days) were observed in peripherally treated animals. In addition, 2 mg/kg of anti-miR-155 was administered at disease onset as defined by body weight loss (90 days of age) with one injection given into the lateral ventricle. Increased rotarod performance, delayed time to reach a neuroscore of 1 (7 days), and increased survival (3 days) were observed. CNS treatment with anti-miR-155 derepressed miR-155 targeted genes in spinal cord microglia.

Nolan et al. (2014) examined miR-29a knockdown after stereotactic injection of 0.12, 0.5 or 1.0 nmoles miR-29a-specific antagonist or control scrambled sequence. By RT-qPCR, the 1.0 nmoles dose gave consistent knockdown across cortex, hippocampus and lumbar spinal cord tissue when compared to scrambled antagonir. MiR-29a knockdown was significant in the cortex and hippocampus compared to scrambled-treated mice at 10 days post-injection. Knockdown was also found in the lumbar spinal cord of these animals. MiR-29a knockdown remained significant in the cortex with some knockdown still present in the hippocampus and lumbar spinal cord at 30 days post-injection. The 1.0 nmoles miR-29a antagonir was administered at 70 days of age to the CNS of SOD1(G93A) and SOD1 WT mice via i.c.v. injection and the disease progression monitored over time. A significant delay in motor dysfunction with knockdown of miR-29a could not be identified. The paw grip endurance test was used to assess the role of miR-29a on motor system in SOD1(G93A) mice. A loss of grip strength over time occurred in both male and female transgenic mice treated with scrambled antagonir. Grip strength tended to be maintained longer in miR-29a antagonist-treated transgenic males and females than scrambled antagonist-treated mice; all transgenic animals declined in grip strength over time. SOD1(G93A) mice treated with miR-29a antagonist tended towards an increased lifespan compared to treatment with scrambled antagonist. While male mice treated with miR-29a antagonist showed a trend towards increased lifespan, female mice had no change in lifespan following treatment with miR-29a antagonist.

In a study by Koval et al. (2013) a large cohort of SOD1(G93A) mice at 60 days of age were treated with continuous intraventricular infusion of anti-miR-155 (n = 22), scrambled control anti-miR (n = 21), or saline (n = 20). Any peripheral role of miR-155 was accounted for by supplementing the CNS treatment with weekly anti-miR or saline intraperitoneally injections. Onset of disease was taken as the age when weight peaked and/or when a neurological score of 1 was observed indicated by abnormal hind limb motility. Treatment and monitoring continued until the animal reached the end stage, which was when the mouse was no longer able to right itself after being placed on its side within 30 seconds. No significant change in disease onset was observed, but survival was significantly increased in the anti-miR-155-treated mice which had a 9.5 day increase over saline-treated mice. The anti-miR-155-treated animals had a disease duration 14.5 days longer than saline-treated mice and 11 days longer than scrambled control anti-miR animals. There was no significant difference in survival or disease duration between scrambled-treated and saline-treated animals.

hSOD1 silencing in SOD1(G93A) mice and rats

Keeler et al. (2019) randomly assigned SOD1(G93A) mice to be treated with AAVrh10-H1-miR(SOD1) (n = 8, 7F/1M) or PBS (n = 7, 6F/1M), and littermate non-transgenic animals (n = 8, 7F/1M) received PBS. The AAVrh10-H1-miR(SOD1) vectors (AAV-miR(SOD1)) targeted the human SOD1 sequence. Vector doses were 1 × 10^11 vector genomes (vg) per animal and were injected into the tongue and intraperitoneal space for a total vector dosage of 2 × 10^11 vg per animal. SOD1(G93A) animals were injected at approximately 60 days of age with either AAV-miR(SOD1) or PBS. Treatment with AAV-miR(SOD1) caused a significant silencing of SOD1 mRNA by 64% in the tongue and 80% in the diaphragm. The lung had a 35% reduction of SOD1 mRNA. There was pronounced silencing systemically in the liver, heart, and hind limb with a significant decrease in expression of 86%, 87%, and 89%, respectively. The medulla and spinal cord also showed suppression of SOD1 mRNA ranging from 23% to 45% but not statistically significant. Targeting the respiratory system by AAV-miR(SOD1) significantly increased survival by an average of 50 days compared to untreated SOD1(G93A) mice. Weight gain was significantly improved in treated compared to untreated SOD1(G93A) mice, with some treated mice maintaining weight until 190 days after being placed on its side. AAV-miR(SOD1)-treated SOD1(G93A) mice had a slower neurological decline compared to untreated SOD1(G93A) mice. Less rapid deterioration of muscle strength...
occurred in AAV-miR(SOD1)-treated SOD1(G93A) mice compared to untreated SOD1(G93A) mice. Breathing decline was lessened in the AAV-miR(SOD1)-treated SOD1(G93A) mice compared to untreated SOD1(G93A) mice.

SOD1(G93A) rats at 65 days of age were injected with an antisense oligonucleotide (ASO) against hSOD1, scrambled ASO, or artificial CSF (aCSF) between L4 and L5 of the lumbar spinal cord by Hoye et al. (2017). At 50 days after treatment with SOD1 ASO, hSOD1 mRNA was significantly decreased (~75%) in the lumbar spinal cord of these animals and hind limb grip strength was preserved. MiR-218 CSF levels were not reduced in scrambled ASO-treated rats but were markedly lowered in the hSOD1 ASO-treated group compared with aCSF-treated littermate controls. Previously published data suggested that miR-218 levels were increased in CSF during MN disease in SOD1(G93A) rats (Howland et al., 2002). The miR-218 CSF levels were selectively responsive to MN function-sparing therapy as shown by CSF levels of neuronal miR-132 and miR-124 being unchanged by SOD1 ASO treatment. Treatment of non-transgenic rats with aCSF, scrambled ASO, or hSOD1 ASO did not affect miR-218 CSF levels. Increased miR-218 CSF levels due to MN loss were consistent with ALS MNs dying by necrosis and subsequently releasing miR-218 and other cellular components. This was tested using primary mouse MNs treated with sodium arsenite whereby miR-218 was increased temporally in the media and this correlated with lactate dehydrogenase activity, an indicator of cell death.

In a study by Stoica et al. (2016), an AAV9 artificial miRNA against hSOD1 was delivered i.c.v. to SOD1(G93A) mice on postnatal day 0–1. Human SOD1 mRNA levels in spinal cord were decreased up to 50% with no significant difference between cervical, thoracic, and lumbar regions. hSOD1 mRNA levels were reduced by >80% in the heart and gastrocnemius muscle, but were unchanged in the liver and lung. There were no changes in the levels of mouse SOD1 mRNA in thoracic spinal cord. Using multiplex ISH, the intensity of hSOD1 mRNA signal was considerably reduced in cells expressing GFP mRNA both in motor cortex and spinal cord. Median survival in AAV9-amiR-SOD1, AAV9-hSOD1 ASO, and GFAP antisense oligonucleotide (ASO) against hSOD1 showed no GFP expression but strong SOD1 expression in MNs. Anti-SOD1 antibodies. A non-injected control primate showed no GFP expression but strong SOD1 expression in MNs. Lumbar spinal cord sections were stained with anti-GFP and anti-SOD1 antibodies. A non-injected control primate showed no GFP expression but strong SOD1 expression in MNs. Animals injected with the preclinical H1 vector (that included GFP) showed GFP expression in most but not all MNs, confirming that AAVrh10 targets MNs. The MNs expressing the GFP protein were not expressing SOD1, whereas GFP-negative MNs in the same tissue sections had SOD1 protein. To assess silencing of SOD1 in MNs, an average of 400 cells were microdissected using laser capture. A significant silencing was shown in MNs with a 1.7-fold and 1.6-fold decrease of SOD1 expression in the H1 and U6 groups, respectively, in the group treated with the CB-miR-SOD1 construct from 18 to 35 days (94%). A similar disease duration was observed for the U6-miR-SOD1-treated (34 days) and the untreated (33 days) group, which indicated the increased survival in this group could be attributed primarily to a delay in disease onset. The treatment efficiently delayed muscle wasting and significantly maintained two and four limbs’ strength. Motor skills were significantly preserved by the treatment as indicated by rotarod performance in mice (120 days or more of age).

Silencing of SOD1 by artificial miRNA in cynomolgus and marmoset monkeys

In a study by Borel et al. (2018), miR-SOD1 was administered intrathecally using AAV.rh10 vector to male cynomolgus monkeys closely matched in age and body weight. The quantity of miR-SOD1 in the spinal cord increased with the relative strength of the promoter (CB < H1 < U6). To precisely assess silencing in the MNs, an average of 400 cells were microdissected using laser capture. A significant silencing was shown in MNs with a 1.7-fold and 1.6-fold decrease of SOD1 expression in the H1 and U6 groups, respectively, in the group treated with the CB-miR-SOD1 construct from 18 to 35 days (94%). A similar disease duration was observed for the U6-miR-SOD1-treated (34 days) and the untreated (33 days) group, which indicated the increased survival in this group could be attributed primarily to a delay in disease onset. The treatment efficiently delayed muscle wasting and significantly maintained two and four limbs’ strength. Motor skills were significantly preserved by the treatment as indicated by rotarod performance in mice (120 days or more of age).
In a previous study by Borel et al. (2016), nine marmosets of similar age (less than 4 years old) and body weight, and with low levels of neutralizing antibody against AAVrh10, received an intrathecal injection at lumbar level of rAAVrh10 encoding one of three constructs CB-GFP, CB-miR-SOD1, and U6-miR-SOD1. The animals were divided into three equal-sized, gender-matched groups, and euthanized at 18-23 days post injection. The females were subsequently excluded from analysis based on uncertainty of needle placement (shown by absence of tail-flick response). MNs were isolated from sections of the spinal cord by laser-capture microdissection. By RT-PCR to quantify SOD1 mRNA levels, SOD1 levels in MNs were decreased with the CB-miR-SOD1 by 21% in the lumbar region and 8% in the cervical region. In addition, SOD1 levels were decreased with the U6-miR-SOD1 by 93% in the lumbar, 65% in the thoracic, and 92% in the cervical region of the spinal cord. There was a positive correlation of the levels of SOD1 silencing with the levels of mature miR-SOD1 expression in the lumbar spinal cord. In the pons and medulla, SOD1 levels were lowered by 20% with the CB-miR-SOD1 and by 55% with the U6-miR-SOD1.

The findings from the studies in SOD1(G93A) and wobbler mice are summarized in Tables 1 and 2.

Discussion

A number of studies have been performed on ALS pathogenic mechanisms using different models but a common pathophysiological mechanism that would aid therapeutic advances has not yet been identified. A familial, genetic background is only detectable in about 10% of patients (fALS), and most of the cases occur sporadically without familial connection (sALS) (Ajroud-Dris et al., 2015). A molecular pathway leading to selective MN degeneration in fALS and sALS is still to be elicited (Cabellero-Hernandez et al., 2016; Taylor et al., 2016). Previous studies have indicated that a programmed mechanism of cell death similar to apoptosis is responsible for MN degeneration in ALS (Martin, 2000; Moser et al., 2013; Dahlke et al., 2015; Rohm et al., 2019). Several inflammatory pathways have been implicated in the progression of the disease and MN degeneration (McCombe et al., 2011). Cytoplasmic inclusions or aggregates in degenerating MNs impair the normal protein homeostasis and promote cellular stress (Saxena and Caroni, 2011). This abnormal protein aggregation has been observed in both fALS and sALS patients (Gruzman et al., 2007) and linked with decreased patient survival (Wang et al., 2008). About 20% of fALS and 30% of sALS patients carry a mutation in the SOD1 gene (Al-Chalabi et al., 1998; Eisen et al., 2008; Borel et al., 2016). Research suggests that conformational instability, misfolding, and some degree of aggregation is responsible for mutant SOD1 protein acquiring neurotoxicity (Prudencio et al., 2016). Misfolded SOD1 inclusions were identified in different glial cells of sALS and fALS patients (Forsberg et al., 2011) and selective deletion of mutant SOD1 expression in astrocytes retarded disease progression in a mouse model (Yamanaka et al., 2008). Astrocytes from both SALS and FALS patients, and from the SOD1(G93A) rodent model, are toxic to MNs (Diaz-Amarilla et al., 2011; Meyer et al., 2014) and these cells, with a reactive profile, were present in the primary motor cortex and gray matter from ALS cases (Kamo et al., 1987; Nagy et al., 1994).

MicroRNAs are altered in neurodegenerative diseases e.g., Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease and may serve as markers of disease and response to therapeutic interventions. Early sensitive biomarkers would assist in the early diagnosis in family members at risk of developing ALS and may help in genetic counseling (Benatar et al., 2016). The findings from the articles reviewed herein have indicated dysregulated levels of miRNA expression in the brain, spinal cords, MNs of spinal cord and brainstem, and hypoglossal, facial, and red motor nuclei of ALS animal models. A large number of miRNAs were upregulated whereas a smaller number were downregulated (Table 1). Among the miRNAs found to be upregulated in two or more of the studies by RT-PCR analysis were miR-21, miR-155, miR-125b, miR-146a, miR-124, miR-9, and miR-19b, while those downregulated in two of the studies included miR-146a, miR-29, miR-9, miR-124, and miR-125b. A change of direction in miRNA expression occurred in some tissues when compared (e.g., miR-29b-3p in cerebellum and spinal cord of wobbler mice at 40 days), or at different disease stages (e.g., miR-200a in spinal cord of SOD1(G93A) mice at 95 days vs. 108 and 112 days). In the latter case, measurement of such miRNAs would provide important information on the extent of disease progression. Furthermore, suppression of miR-129-5p resulted in increased lifespan, improved muscle strength, reduced NMJ degeneration, and tended to improve MN survival in the SOD1(G93A) mouse model. Suppression of miR-155 was also associated with increased lifespan, while lowering of miR-29a tended to improve lifespan in males and increase muscle strength in SOD1(G93A) mice. Overexpression of members of miR-17–92 cluster improved MN survival in SOD1(G93A) mice and increased lifespan. Moreover, treating only with an artificial miRNA designed to target hSOD1, while not a naturally occurring miRNA that may have a role in disease progression (e.g., in the study by Borel et al. (2016), it was engineered on the backbone of cellular miR-155), was shown to be effective in extending survival in SOD1(G93A) mice (Borel et al., 2016) and also significantly silenced SOD1 expression of MNs in male monkeys (Borel et al., 2016, 2018). From the SOD1(G93A) mouse studies reviewed herein, a small number of miRNAs were dysregulated at the presymptomatic stage e.g., miR-206 and miR-155 both upregulated, while a large number were dysregulated in the early symptomatic and late stage of disease (Table 1). It seems plausible that the miRNA changes found in the presymptomatic stage could be contributing to the initiation of the disease, while those occurring in the early symptomatic and late stage could be as a consequence of the disease process itself. Notably, many of the positive findings identified by modifying miRNA levels by intracerebroventricular or intrathecal treatment with agonism or antagonism (Table 2) were achieved by administration at the presymptomatic stage. There is a need for further studies to be performed on modifying miRNA levels in SOD1(G93A) mice at the presymptomatic stage and to compare using the same animal model with miRNA levels modified at the symptomatic stage. Interestingly, both the studies by Borel et al. (2016) and Stoica et al. (2016) that showed an amelioration of the disease process by suppressing hSOD1 had administered an artificial miRNA based on the miR-155 sequence to SOD1(G93A) mice in the presymptomatic stage. MiR-155 could be an important contender for future therapeutic manipulation. Downstream effects of miRNA dysregulation could be important in initiating the disease process. For instance, Tung et al. (2019) showed downregulation of miR-17 in lumbar spinal cord MNs at 80 days and increased expression of one of its targets, phosphatase and tensin homologue (PTEN), in MNs at 100 days. PTEN has been linked to the pathogenesis of neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and ALS (Ismail et al., 2012).

With regard to human studies, Figueroa-Romero et al. (2016) identified 90 mature differentially expressed miRNAs in postmortem spinal cord tissue from 12 SALS compared to 12 control subjects, among which nearly all were decreased and only miR-155 and miR-142-5p were increased. Similarly, miR-155 and miR-142-5p were increased in the spinal cord of the SOD1(G93A) mouse model. MiR-125b and miR-29b were downregulated in the postmortem spinal cord tissue of sALS patients. MiR-29b-3p was downregulated in spinal cord at 40 days in wobbler mice. However, miR-125b was upregulated in spinal cord at symptomatic stage (12–14...
| Reference | Animal model, gender | Sample | Stage of disease | MiRNA analysis method | Upregulation of miRNAs | Downregulation of miRNAs |
|-----------|---------------------|--------|------------------|----------------------|------------------------|--------------------------|
| **Spinal cord of SOD1(G93A) mice** | | | | | | |
| Loffreda et al., 2020 | SOD1(G93A) mice, female | Lumbar spinal cord | Presymptomatic, 10 wk; early symptomatic 15 wk, end stage 22 wk | RT-PCR | miR-206 | |
| Loffreda et al., 2020 | SOD1(G93A) mice, female | Lumbar spinal cord | Early symptomatic 15 wk | RT-PCR | miR-129-5p, miR-200c | |
| Tung et al., 2019 | SOD1(G93A) mice | Lumbar spinal cord | 80 d | RT-PCR | miR-17 | |
| Tung et al., 2019 | SOD1(G93A) mice | Lumbar spinal cord | 100 d | RT-PCR | miR-17, miR-18a, miR-20a | |
| Zhou et al., 2018 | SOD1(G93A) mice | Spinal cord | 95, 108, 122 d | RT-PCR | miR-219, miR-21, miR-191a | |
| Zhou et al., 2018 | SOD1(G93A) mice | Spinal cord | 95 d | RT-PCR | miR-200a, miR-124 | |
| Zhou et al., 2018 | SOD1(G93A) mice | Spinal cord | 108, 122 d | RT-PCR | miR-125b | |
| Cunha et al., 2018 | SOD1(G93A) mice, male | Ventral horn of spinal cord | Presymptomatic 4–6 wk | RT-PCR | miR-155 | |
| Cunha et al., 2018 | SOD1(G93A) mice, male | Ventral horn of spinal cord | Symptomatic 12–14 wk | RT-PCR | miR-155, miR-125b, miR-146a, miR-21, miR-124 | |
| Hoye et al., 2017 | SOD1(G93A) mice | MNs of spinal cord and brainstem | 63 d | RT-PCR | miR-218-5p, miR-218-2-3p, miR-138, miR-133a, miR-1193 | |
| Hoye et al., 2017 | SOD1(G93A) mice | Spinal cord | 126 d | RT-PCR | miR-218-5p, miR-138 | |
| Parisi et al., 2016 | SOD1(G93A) mice | Whole spinal cord | Late stage 18 wk | RT-PCR | miR-125b | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | Spinal cord | 4 mon | RT-PCR | miR-19a, miR-19b, miR-133a, miR-133b, miR-9, miR-29, miR-330, miR-1 | |
| Dobrowolny et al., 2015 | MLC/ SOD1(G93A) mice | Spinal cord | 95, 108, 122 d | RT-PCR | miR-29a | |
| Nolan et al., 2014 | SOD1(G93A) mice | Spinal cord | Presymptomatic 70 d Symptomatic 90 d | RT-PCR | miR-9 | |
| Zhou et al., 2013 | SOD1(G93A) mice | Spinal cord | 95, 108, 122 d | RT-PCR | miR-17, miR-19b, miR-20a, miR-24-2-5p, miR-106a, miR-142-3p, miR-142-5p, miR-146a, miR-146b, miR-155, miR-223, miR-338-3p | |
| Koval et al., 2013 | SOD1(G93A) mice | Spinal cord | End stage | Microarray analysis | miR-9 | |
| **Cortical tissue of SOD1(G93A) mice** | | | | | | |
| Gomes et al., 2019 | SOD1(G93A) mice | Cortical tissue | Presymptomatic 4–6 wk | RT-PCR | miR-146a | |
| Gomes et al., 2019 | SOD1(G93A) mice | Cortical tissue | Symptomatic 12–14 wk | RT-PCR | miR-125b, miR-21, miR-146a | |
| **Whole brain, brain regions of SOD1(G93A) mice** | | | | | | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | Whole brain | Presymptomatic 8 wk | RT-PCR | miR-9 | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | Whole brain | Late stage 18 wk | RT-PCR | miR-9, miR-124a, miR-19a, miR-19b | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | SVZ, primary motor cortex, hippocampus, brainstem MN | Late stage 18 wk | RT-PCR | miR-124a | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | SV2, hippocampus | Late stage 18 wk | RT-PCR | miR-9 | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | Hippocampus, brainstem MN | Late stage 18 wk | RT-PCR | miR-19a | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | Primary motor cortex, brainstem MN | Late stage 18 wk | RT-PCR | miR-19a, miR-125b | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | Primary motor cortex, hippocampus | Late stage 18 wk | RT-PCR | miR-19b | |
| Marcuzzo et al., 2015 | SOD1(G93A) mice | SV2 | Late stage 18 wk | RT-PCR | miR-19b | |
| **Spinal cord of wobbler mice** | | | | | | |
| Klatt et al., 2019 | Wobbler mice | Spinal cord | 0 d | RT-PCR | miR-29b-3p | |
| Klatt et al., 2019 | Wobbler mice | Spinal cord | 40 d | RT-PCR | miR-29b-3p | |
| **Cerebellum of wobbler mice** | | | | | | |
| Klatt et al., 2019 | Wobbler mice | Cerebellum | 0 d | RT-PCR | miR-29b-3p | |
| Klatt et al., 2019 | Wobbler mice | Cerebellum | 40 d | RT-PCR | miR-29b-3p | |

Expression levels of miRNAs in amyotrophic lateral sclerosis (ALS) animals compared to control animals. MN: Motor neuron; RT-PCR: real-time quantitative polymerase chain reaction; SVZ: subventricular zone.
Table 2 | Alterations in SOD1(G93A) animal models of amyotrophic lateral sclerosis following overexpression/suppression of specific miRNAs or silencing of hSOD1

| Overexpression of miRNA | Suppression of a specific miRNA or hSOD1 | Animal model, gender | Route of administration, age of animals | Improved body weight gain | Increased lifespan | Improved muscle strength | Improved MN survival | Counteracted NMI degeneration | Reference |
|-------------------------|----------------------------------------|---------------------|----------------------------------------|--------------------------|-------------------|------------------------|----------------------|--------------------------|-----------|
| miR-129-5p              | SOD1(G93A) mice, males and females     | i.c.v., 80 d of age, early symptomatic | √                        | √                        |                   |                       |                |                           |           |
| miR-17–92               | SOD1(G93A) mice                       | i.t., 60 d of age   | √                        |                           |                   |                       |                |                           |           |
| miR-155                 | SOD1(G93A) mice                       | i.p., 82 d of age; i.c.v., 90 d | √                        |                           |                   |                       |                |                           |           |
| miR-29a                 | SOD1(G93A) mice, males and females    | i.c.v., 70 d of age | Trend in males, but not in females    | Trend shown in males and females |                   |                       |                |                           | Nolan et al., 2014 |
| miR-155                 | SOD1(G93A) mice                       | i.c.v. + i.p., 60 d of age | √                        |                           |                   |                       |                |                           | Koval et al., 2013 |
| hSOD1                   | SOD1(G93A) mice                       | into intrapleural space, 60 d of age | √                        | √                        | √                 |                       |                |                           | Keeler et al., 2019 |
| hSOD1                   | SOD1(G93A) mice                       | i.t., 65 d of age   | √                        |                           |                   |                       |                |                           | Hoyer et al., 2017 |
| hSOD1                   | SOD1(G93A) mice                       | i.c.v., 0–1 d of age| √                        |                           |                   |                       |                |                           | Stoica et al., 2016 |
| hSOD1                   | SOD1(G93A) mice                       | i.v., 56–68 d of age| √                        | √                        | √                 |                       |                |                           | Borel et al., 2016 |

√ indicates this was observed in the study; in Borel et al. (2016) the miR-SOD1 was designed based on the backbone of cellular miR-155; in Stoica et al. (2016) the amiR-SOD1 targeted the coding sequence of the human SOD1 gene and used the endogenous murine miR-155 flanking sequences. i.c.v.: intracerebroventricular; i.p.: intraperitoneal; i.t.: intrathecal; i.v.: intravenous; miRNA: microRNA; MN: motor neuron; NMI: neuromuscular junction; SOD1: Cu/Zn superoxide dismutase 1.

weeks) and end stage (~23 weeks) of SOD1(G93A) mice. Other miRNAs downregulated in postmortem spinal cord tissue from sALS patients included let-7e, miR-140-3p, miR-133b, miR-148b-5p, and miR-577 (Figuerola-Romero et al., 2016). Also, Koval et al. (2013) observed that miR-243-2*, miR-142-3p, miR-142-5p, miR-146a, miR-146b, and miR-155 were upregulated in postmortem spinal cord samples from 16 ALS patients compared to 12 control subjects, and showed that miR-155 was upregulated in 11 sALS and 5 fALS patients (1.7x increase for both compared to controls). Other studies on miRNAs in postmortem spinal cords were performed with much smaller numbers of sALS patients and control subjects (Campos-Melo et al., 2013; Ishaq et al., 2014). Wakabayashi et al. (2014) found that 91 miRNAs were upregulated and 233 downregulated in postmortem cerebral cortex samples from 6 sALS compared to 4 control subjects. MiR-494 (+4.99-fold change) was the most highly differentially upregulated miRNA, followed in order by miR-4257, miR-24-3p, miR-4299, and miR-1973 as the top five downregulated miRNAs, whereas miR-4740-5p (+0.19-fold change) was the most highly differentially upregulated miRNA, followed in order by miR-4257, miR-24-3p, miR-4299, and miR-1973 as the top five downregulated miRNAs. None of these miRNAs were dysregulated in cortical tissue samples from SOD1(G93A) mice in the articles reviewed. Thus, although there have been few studies on miRNA expression in postmortem spinal cord and brain samples of sALS and fALS patients to compare with, does appear to be some similarities of miRNA expression in spinal cord samples from ALS mouse models. As the C9orf72 gene is the most prevalent mutated gene among ALS patients, it would be relevant to determine miRNA expression of spinal cord and brain samples in the FVB-C9orf72 BAC transgenic mouse model of ALS. In addition, miRNA expression should be examined in the brain and spinal cord of vervet monkeys (Chlorocebus sabaeus) fed the cyanoxin β-N-methylamino-L-alanine and may serve as a nonhuman primate model of ALS that better matches the human patient population (Davis et al., 2020).

Attention was drawn to possible explanations for a difference in findings in C9orf72 mice between the studies of Liu et al. (2016) and Mordes et al. (2020). One possible explanation was the relatively small number of animals in the study by Liu et al. (2016). In fact, many of the reviewed studies had employed small-sized groups of animals (~10–12 or less per group). Future studies that are performed with much larger cohorts of animals would be more informative and the findings less likely to be refuted. Furthermore, most of the studies reviewed did not report the gender of the animals used, or if they had, it was only males or females. Clearly studies need to be performed with approximately equal and a sufficient number of male and female animals, so that the findings can be statistically analyzed in both. Gender differences in the composition of groups could constitute a confounding factor and statistical analyses of data should be corrected by performing multiple comparisons. Also, normalization of miRNA data should be performed using normalizing miRNA species, but this was only reported in eight of the studies reviewed. It is not clear whether it was included in the remaining studies.

Novel therapies aimed at silencing SOD1 include inhibitory short hairpin RNA, artificial miRNA, ASOs, and virally delivered silencing elements. In the studies reviewed, an artificial miRNA targeting hSOD1 delivered i.t. by ASO or i.v. by AAVrh10 to ALS mice resulted in increased lifespan, and improved muscle strength. These changes were also seen using an AAV9 artificial miRNA against hSOD1 delivered i.c.v. (Table 2). Recently the US Food and Drug Administration approved an ASO therapeutic agent, Nusinersen, for spinal muscular atrophy. This provides a successful model of intervention in other MN diseases, including ALS (Parente and Corti, 2018). SOD1 ASOs have been shown to be safe in humans (Miller et al., 2013) and a clinical trial is currently underway to treat SOD1-related ALS using a second-generation ASO, Tofersen (BIIB067, Ionis-SOD1Rx, ASO1) (ClinicalTrials.gov., 2020).
In conclusion, genetic animal models of ALS show some of the changes in miRNA expression that have been reported in the spinal cord of SALS and FALS patients. They have proven to be useful in testing possible therapies for ALS e.g., human SOD1 mRNA was decreased in spinal cords of SOD1(G93A) mice with approximately 75% reduction of SOD1 following a single intraventricular injection of ASO 1 or ASO 2. Similar dose-dependent reductions in human SOD1 mRNA were achieved in SOD1(G93A) rats with ASO 1 and ASO 2 (McCampbell et al., 2018). This review underlines the importance and need for further studies with ALS animal models, especially nonhuman primates, specifically testing ASOs or AAV vectors carrying miRNAs to target human SOD1 or other genes to provide a more effective means of treating ALS and slowing its progression, and which hopefully may be successfully translated to human ALS patients.

Author contributions: Both authors contributed equally to and approved the final version of the manuscript.

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Abe K, Aski M, Tsui S, Itoyama Y, Soubi G, Togo M, Hamasda C, Tanaka M, Akimoto M, Nakamura K, Takahashi F, Kondo K, Yoshino H (2011) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:505-512.

Achi EY, Rudnicka SA (2012) ALS and frontotemporal dysfunction: a review. Neurol Res 34:906-913.

Ajroud-Driss S, Siddique T (2015) Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 1852:679-684.

Al-Chalabi A, Andersen PM, Chiozza B, Shaw C, Sham PC, Robberecht W, Matthijs G, Camu W, Marklund SL, Forsgren L, Rouleau G, Laing NG, Nurse PV, Siddique T, Leigh PN, Powell IF (1998) Recessive amyotrophic lateral sclerosis families with the D90A-SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 7:2045-2050.

Al-Chalabi A, Hardman O (2013) The epidemiology of ALS: a conspiracy of genes, its progression, and which hopefully may be successfully translated to human ALS patients.

Author contributions: Both authors contributed equally to and approved the final version of the manuscript.

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Abe K, Aski M, Tsui S, Itoyama Y, Soubi G, Togo M, Hamasda C, Tanaka M, Akimoto M, Nakamura K, Takahashi F, Kondo K, Yoshino H (2011) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 10:505-512.

Achi EY, Rudnicka SA (2012) ALS and frontotemporal dysfunction: a review. Neurol Res 34:906-913.

Ajroud-Driss S, Siddique T (2015) Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 1852:679-684.

Al-Chalabi A, Andersen PM, Chiozza B, Shaw C, Sham PC, Robberecht W, Matthijs G, Camu W, Marklund SL, Forsgren L, Rouleau G, Laing NG, Nurse PV, Siddique T, Leigh PN, Powell IF (1998) Recessive amyotrophic lateral sclerosis families with the D90A-SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 7:2045-2050.

Al-Chalabi A, Hardman O (2013) The epidemiology of ALS: a conspiracy of genes, its progression, and which hopefully may be successfully translated to human ALS patients.

Author contributions: Both authors contributed equally to and approved the final version of the manuscript.

Conflicts of interest: The authors declare no conflicts of interest.

Financial support: None.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Plagiarism check: Checked twice by iThenticate.

Peer review: Externally peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References
Nagy D, Kato T, Kushner PD (1994) Reactive astrocytes are widespread in the cortical gray matter of amyotrophic lateral sclerosis. J Neurosci Res 38:336-347.

Nardo G, Trolese MC, Tortarolo M, Vallarola A, Freschi M, Pasetto I, Bonetto V, Pirelli M, van den Bercken-Caspari T (2011) New insights on the mechanisms of disease course variability in ALS from muscle pathology. Brain Pathol 21:327-347.

Nolan K, Mitchum MR, Jimenez-Mateos EM, Henschall DC, Concannon CG, Prehn JH (2014) Increased expression of microRNA-29a in ALS mice: functional analysis of its inhibition. J Mol Neurosci 53:231-241.

O’Rourke JB, Bödiker M, Liu W, Kurniawan MA, Cibik A, Chen Y, O’Malley A, Natarajan N, Neafsey DJ, Kedersha NL, Hentati A, Donaldson D, Goto J, Rohm M, May C, Marcus K, Steinbach S, Theis V, Theiss C, Matschke V (2019) The miR-124 microRNA signature in familial amyotrophic lateral sclerosis patient survival. PLoS One 14:e0214591.

Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis. Nat Rev Neurol 10:661-670.

Russell AP, Wada S, Vergani L, Hock MB, Lamon S, Léger B, Ushida T, Cartoni R, Wadley NV, Elliott J, Al-Chalabi A (2015) The progressive B5SG rat model of Parkinson’s: recapitulating multiple key features of the human disease. PLoS One 10:e0139694.

Tauc M, Bajic VB, Brotchi J, Thiebaut M, Church N, Knowles J, Dumas F, Flament S, Fournier J, Sanchez C, Fournier Y, Deslys JP, van den Bercken-Caspari T, Bremer Y, Al-Chalabi A, Léger B, Ushida T, Cartoni R, Wadley NV, Elliott J, Al-Chalabi A, Luo Y, Garcia-Albiach O, Shi W, Chen Y, Khalil AM, Rice S (2014) Wild-type human TDP-43 expression causes TDP-43 accumulation, motor deficits, and early mortality in transgenic mice. J Neurosci 34:10851-10859.

Yokoseki A, Shiga A, Tan CF, Tagawa A, Kaneko H, Koyama A, Eguchi H, Tsujino A, Ikeuchi T, Hasegawa S, Akitoshi Y, Oue S, Masuda H, Segawa T, Itoh Y, Kuroda H, Kusumoto K, Koike M, Maeda Y, Maruyama K, Nose Y, Tsuchida M, Minamino N, Oomura Y, Ono K (2014) Increased expression of microRNA-206 delays ALS progression and promotes regeneration of neurovascular synapses in mice. Science 342:1549-1554.

Wilson JM, Khabazian I, Wong MC, Seydakallahi A, Bains JS, Pasqualeotto BA, Williams AH, Valdez G, Moresi V, Qi X, McAnally J, Elliott JL, Bassel-Duby R, Sanes JR (2015) Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival. PLoS Biol 13:e1002216.

Wilson JM, Baranowski DC, Robertson HA, Shaw CA, Kay DG (2015) The progressive B5SG rat model of Parkinson’s: recapitulating multiple key features of the human disease. PLoS One 10:e0139694.

Yoshikawa H, Al-Chalabi A, Luo Y, Garcia-Albiach O, Shi W, Chen Y, Khalil AM, Rice S (2014) Wild-type human TDP-43 expression causes TDP-43 accumulation, motor deficits, and early mortality in transgenic mice. J Neurosci 34:10851-10859.

Zhou F, Guan Y, Chen Y, Zhang C, Yu, Gao H, Du H, Liu B, Wang X (2013) miRNA-9 expression is upregulated in the spinal cord of G93A-SOD1 transgenic mice. J Intell Exp Pathol Sclerosis. Mice. PLoS Med 10:e1001434.

The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 10:661-670.